Used in targeted cancer therapies, particularly for non-small cell lung cancer, colorectal cancer, and head and neck cancer, where EGFR overexpression is common, especially in metastatic or recurrent cases. This antibody inhibits EGFR signaling, reducing tumor growth and cell proliferation. It is also employed in combination with chemotherapy or radiation to enhance treatment efficacy. Its high specificity makes it valuable in diagnostic assays and imaging to detect EGFR-expressing tumors. Additionally, it serves as a reference standard in biosimilar development and preclinical research to evaluate new anti-EGFR agents. It is currently under investigation for other EGFR-dysregulated tumors.